Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02079610 · ClinicalTrials.gov registry record · NA
Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases
A NA study, sponsored by Laureate Institute for Brain Research.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT02079610: Completed NA study, sponsored by Laureate Institute for Brain Research.
NCT02079610 is a NA study that has completed, run by Laureate Institute for Brain Research. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02079610, a NA study, has completed, sponsored by Laureate Institute for Brain Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether upregulating the left amygdala during positive autobiographical memory recall via real time functional magnetic resonance imaging neurofeedback will lead to an improvement in clinician administered ratings of depressive symptoms. The investigators predict that patients with major depressive disorder receiving left amygdala neurofeedback will increase their amygdala response during positive autobiographical memory recall compared to those receiving control feedback from a region not involved in emotional processing and that this ability will be associated with clinically significant improvement.
Primary Outcome
Depression symptom severity rating scale. The overall score ranges on MADRS are from from 0 to 60, with higher scores indicating more severe depression. Usual cutoff points are: 0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression \>34 - severe depression
Interventions
- BEHAVIORAL real-time fMRI neurofeedback: Amygdala
- BEHAVIORAL real-time fMRI neurofeedback: HIPS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-04 |
| Phase | NA |
What the finished NCT02079610 record still lists
NCT02079610 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which real-time fMRI neurofeedback: Amygdala is the first listed.
NCT02079610 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02079610 about?
NCT02079610 is a clinical study titled "Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases". The purpose of this study is to determine whether upregulating the left amygdala during positive autobiographical memory recall via real time functional magnetic resonance imaging neurofeedback will lead to an improvement in clinician administered ratings of depressive symptoms. The investigators pr...
What is the current status of trial NCT02079610?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2014-04. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02079610?
The interventions under investigation include: real-time fMRI neurofeedback: Amygdala (BEHAVIORAL), real-time fMRI neurofeedback: HIPS (BEHAVIORAL).
Who is sponsoring clinical trial NCT02079610?
This trial is sponsored by Laureate Institute for Brain Research, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02079610's enrollment target sits among peer trials
36 1541st of 2000 higher than 437 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia